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Value of the data {#sec0001a}
=================

•These data obtained directly from human samples suggests Ang-(1-12)/chymase might be involved in the development of cardiovascular disease.•The data provide a basis for further investigation of cardiac angiotensin II production through a renin-independent pathway.•These data has highly significant clinical implications because intracellular chymase-mediated Ang II formation is unaffected by ACE inhibitors or angiotensin II type 1 (AT1) receptor antagonists.

1. Data Description {#sec0001}
===================

[Table 1](#tbl0001){ref-type="table"} documents the state of cardiac function prior to surgical intervention. Mean left ventricular ejection fraction (LVEF) was preserved across all groups of patients except in those patients who underwent coronary artery bypass graft (CABG) surgery, where it was slightly reduced. When compared to the CABG only group, peak velocities of early mitral blood flow were higher in mitral valve repair groups with and without concomitant CABG. There were no other differences in echocardiographic parameters of left ventricle function or morphology between patients undergoing the different cardiac surgery procedures.Table 1Main Echocardiographic VariablesTable 1Surgical ProceduresVariableAortic Valve Repair (only) (n = 23)Mitral Valve Repair (only) (n = 19)Coronary Artery Bypass Graft + Mitral Valve Repair (n = 6)Coronary Artery Bypass Graft + Aortic Valve Repair (n = 7)Coronary Artery Bypass Graft (n = 56)LVEF, %56.70 ± 1.25\*55.89 ± 1.6953.33 ± 1.6855.57 ± 2.6549.19 ± 1.58LA diameter, cm4.15 ± 0.204.57 ± 0.365.70 ± 0.714.04 ± 0.194.00 ± 0.13E max, cm/s95.69 ± 7.20128.61 ± 12.13\*120.60 ± 15.00\*82.92 ± 12.3477.30 ± 3.75E/A ratio1.42 ± 0.251.89 ± 0.401.36 ± 0.211.00 ± 0.121.28 ± 0.11IVS diameter, cm1.28 ± 0.051.15 ± 0.071.06 ± 0.111.41 ± 0.201.24 ± 0.04LVID diastolic, cm4.75 ± 0.134.69 ± 0.254.83 ± 0.574.65 ± 0.254.59 ± 0.12LVID systolic, cm3.34 ± 0.153.11 ± 0.183.53 ± 0.673.15 ± 0.303.31 ± 0.15LVPW diameter, cm1.45 ± 0.171.10 ± 0.071.12 ± 0.081.32 ± 0.101.22 ± 0.04[^2]

We combined all the male and female patients for the data analysis. As shown in [Fig. 1](#fig0001){ref-type="fig"}, the left atrial (LA) chymase activity tended to be higher in congestive heart failure (CHF) versus non-CHF patients (p=0.054), while there was no statistical difference at chymase mRNA level between these two groups. In comparison of patients with stroke vs. non-stroke, chymase activity did not differ between these two groups, but LA chymase mRNA level was markedly higher in patients with stroke compared with non-stroke patients (p=0.009). Similarly, although there was no difference of LA chymase activity between patients with history of postoperative atrial fibrillation (PostOp AF) and patients *without* PostOp AF, LA chymase mRNA was significantly higher in PostOp AF patients vs. non-PostOp AF patients (p=0.009). LA Ang-(1-12) level tended to be higher in the patients with PostOp AF in comparison to non-PostOP AF patients (8.27 ± 1.29 vs. 3.36 ± 0.30, p=0.051).Fig. 1**Left atrial (LA) chymase mRNA, activity, and Ang-(1-12) in diseased hearts. (A-C)** Comparisons of LA chymase activity in patients with CHF vs. non-CHF, stroke vs. non-stroke, and PostOp AF vs. non PostOp AF. **(D-F)** Comparisons of LA chymase mRNA levels in patients with CHF vs. non-CHF, stroke vs. non-stroke, and PostOp AF vs. non PostOp AF. **(G)** LA Ang-(1-12) levels in patients with and without PostOp AF. Numbers in the bars represent the sample size for the corresponding data. Values are means ± SE. Ang-(1-12): angiotensin-(1-12); CHF: congestive heart failure; PostOp AF: postoperative atrial fibrillation.Fig 1

2. Experimental Design, Materials, and Methods {#sec0002}
==============================================

2.1. Ethic statement {#sec0003}
--------------------

The study was approved by the Wake Forest University Health Sciences (IRB 22619). Atrial appendages were obtained from 111 patients undergoing cardiac surgery at the Wake Forest Baptist Medical Center (Winston-Salem, NC, USA). Left atrial appendages were resected during cardiopulmonary bypass for correction of left cardiac valve replacement \[aortic valve replacement (AVR), mitral valve regurgitation (MVR)\], or coronary artery bypass grafting (CABG). Preoperative transthoracic echocardiograms and consent forms were obtained prior to cardiac surgery.

2.2. Echocardiography {#sec0004}
---------------------

Preoperative transthoracic echocardiograms were performed by highly trained sonographers using a 1-5 MHz phased array transducer (Philips S5-1) and Philips iE33 sector scanner (Philips Medical Systems, Andover, MA). Digitally-stored images were reviewed and final reports were completed off-line (Xcelera 3.1; Koninklijke Philips Electronics, Amsterdam, The Netherlands) by cardiologists board certified in adult echocardiography. The preoperative transthoracic echocardiograms reported here were the studies most proximate to the patient\'s surgery. An experienced investigator trained in perioperative echocardiography (LG), who was masked to biochemical and histological findings, manually reviewed all stored images in conjunction with the archived echocardiographic report. Transthoracic echocardiograms were performed and analyzed according to American Society of Echocardiography recommendations [@bib0002]. Left ventricular end-diastolic and end-systolic internal diameters (LVID and LVIS, respectively), and end diastolic LV posterior wall (LVPW) and interventricular septal diameters (IVS) and left ventricular end-systolic left atrial diameter measurements were acquired and measured from the parasternal long-axis view using two-dimensional guided M-mode echocardiography by the leading edge-to-leading edge technique. Left ventricular end diastolic and end systolic volumes (EDV and ESV, respectively) and left atrial volume at end ventricular systole were measured by the biplane method of disks (modified Simpson\'s rule) using apical 4-chamber and apical 2-chamber. Left ventricular ejection fraction was calculated as LVEF (%) = \[(EDV-ESV/EDV)\] × 100%. Mitral inflow measurements of early and late filling velocities were obtained using pulsed Doppler, with the sample volume placed at the tips of mitral leaflets from an apical four-chamber orientation. The early-to-late filing velocity ratio (E/A) was calculated in those patients who were in sinus rhythm at the time of the examination.

2.3. Ang-(1-12) immunohistochemistry {#sec0005}
------------------------------------

Human angiotensin-(1-12) was synthetized for us by AnaSpec Inc. (San Jose, CA). Immunohistochemistry was performed using an affinity purified polyclonal antibody directed to the COOH-terminus of the full length of the sequence of human Ang-(1-12) \[Asp^1^-Arg^2^-Val^3^-Tyr^4^-Ile^5^-His^6^-Pro^7^-Phe^8^-His^9^-Leu^10^-Val^11^-Ile^12^\]. Excised segments of the left and right atrial appendages were immediately immersed in a solution of 4% paraformaldehyde for 24 h and then transferred into 70% ethanol. After dehydration, the tissues were embedded in paraffin and cut into 5 µm thick sections. Slides were warmed for 1 h (55°C), deparaffinized in xylene, and, after being subsequently dipped in serial solutions of ethanol (100%, 95%, 85% and 70%), were rinsed in phosphate buffered saline (PBS). The slides were incubated in an antigen retrieval buffer (Antigen Unmasking Solution H-3300; Vector Laboratories Inc., Burlington, CA) and washed with double distilled water. Slides were then incubated for 5 min in 3% hydrogen peroxide to block the endogenous peroxidase. The sections were blocked with 1% bovine serum in PBS with 5% normal goat serum for 1 h at room temperature and then incubated with the affinity-purified human Ang-(1-12) primary antibody (1:1000 dilution in 1% BS in PBS with 5% normal goat serum) overnight at 4°C. Sections independently treated with 5% normal goat serum in the absence of the primary antibody served as negative controls. Additional controls included sections treated with the primary antibody preincubated with a 20-fold excess of human Ang-(1-12) peptide. In prior studies, we documented that this human Ang-(1-12) antibody does not cross-react with either Ang I or Ang II \[[@bib0003],[@bib0004]\]; however, we observed cross reactivity with human angiotensinogen (AGT). Although literature describes low, if any, expression of angiotensinogen in the human heart [@bib0005], additional sections were incubated with human angiotensinogen antibody (IBL, MN, 1:50). After incubating with the primary antibody, each section was washed three times in PBS. The sections were blocked with 1% BS in PBS with 5% normal goat serum for 1 h at room temperature and then incubated with biotinylated goat anti-rabbit secondary antibody (1:400 dilutions in 1% bovine serum in PBS with 5% normal goat serum; Vector Laboratories Inc., Burlington, CA) for 3 h. After washing the secondary antibody with PBS, sections were stained with 3,3'-diaminobenzidine (DAB, Sigma-Aldrich Chemical Co. St. Louis, MO) in Tris-buffered saline (0.05 mol/L, pH 7.65), and counterstained with hematoxylin before being dehydrated and mounted. The Ang-(1-12) staining-positive rates were calculated using Image J software ([http://imagej.nih.gov/ij/](http://http://imagej.nih.gov/ij/){#interref0001}), a public domain Java image processing program developed by the National Institutes of Health.

2.4. Chymase activity assay {#sec0006}
---------------------------

Native plasma membranes (PMs) were prepared as described previously \[[@bib0003],[@bib0004]\]. Frozen atrial tissue (30-60 mg) was homogenized at 4°C in 1 mL reaction buffer (25 mM HEPES, 125 mM NaCl, and 10 mM ZnCl~2~, pH 7.4) using a Tissue Lyzer (Qiagen, Inc., Valencia, CA) for 90 seconds at 20 Hz. The homogenate was centrifuged at low spin (200 g) for 1 minute at 4°C to remove the connective tissue and cell debris. The supernatant was transferred into a new tube and centrifuged at 28,000 g for 20 minutes at 4°C. The pellet (native membranes) was resuspended in the reaction buffer and stored at -80°C until assayed for chymase activity.

^125^I-Ang-(1-12) metabolism by human atrial tissue PMs were studied in the absence or presence of the chymase inhibitor chymostatin. Highly purified human ^125^I-Ang-(1-12) substrate \[1 nmol/L of ^125^I-Ang-(1-12)\] was added to native PMs in the presence of a mixture of enzyme and peptidase inhibitors (chymostatin, lisinopril, MLN-4760, SCH39370, amastatin, bestatin, benzyl succinate and p-chloromercuribenzoate; each 50 µM) or in the absence of chymostatin only for 30 minutes at 37°C. At the end of the incubation time the reaction was stopped by adding equal volume of 1% phosphoric acid, mixed well, centrifuged (28,000 g for 20 minutes to remove the native PMs) and stored at 4°C. On the day of analysis, the samples were filtered before separation by reverse-phase high-performance liquid chromatography (RP-HPLC). We used a linear gradient from 10% to 50% mobile phase B at a flow rate of 0.35 mL/minute at 32°C. The solvent system consisted of 0.1% phosphoric acid (mobile phase A) and 80% acetonitrile/0.1% phosphoric acid (mobile phase B). Eluted ^125^I products, monitored by an in-line flow-through gamma detector (BioScan Inc., Washington, DC), were identified by comparing them with the retention time of synthetic standard ^125^I peptides. Data were analyzed using Shimadzu LC Solution acquisition software (Kyoto, Japan). The metabolic products are documented as the percent of Ang peptide fractions generated from the parent substrate by chymase. Chymase activity was calculated as the amount of parent ^125^I-Ang-(1-12) hydrolyzed into specific ^125^I-Ang II in the absence or presence of chymostatin and reported as fmoles of Ang II generated from the parent ^125^I-Ang-(1-12) in fmol/mg/min.

2.5. Analysis of gene expression by quantitative real-time PCR {#sec0007}
--------------------------------------------------------------

Quantitative real-time PCR was used to detect gene mRNA levels in human atrial tissue. Total RNA was extracted from frozen, pulverized atria using TRIzol Reagent and processed according to the manufacturer\'s recommendations. The quality and quantity of RNA samples were determined by spectrometry and agarose gel electrophoresis. Complementary first strand DNA was synthesized from oligo (dT)-primed total RNA, using the Omniscript RT kit (Qiagen Inc, CA). Relative quantification of mRNA levels by real-time PCR was performed using a SYBR Green PCR kit (Qiagen Inc. CA). Amplification and detection were performed with QuantStudio 3 Real-Time PCR Systems (Thermo Fisher Scientific Inc.). Only one peak from the dissociation curve was found from each pair of oligonucleotide primers tested. Real-time PCR was carried out in duplicate; a no-template control was included in each run to check for contamination. It was also confirmed that no amplification occurred when samples were not subjected to reverse transcription. Sequence-specific oligonucleotide primers were designed according to published GenBank sequences ([www.ncbi.nlm.nih.gov/Genbank](http://www.ncbi.nlm.nih.gov/Genbank){#interref0002}) and confirmed with Oligo-Analyzer 3.0. The relative target mRNA levels in each sample were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

2.6. Statistics {#sec0008}
---------------

Differences between groups were evaluated by the Student\'s t-test for unpaired analysis. In evaluating differences among echocardiographic variables, Kruskal-Wallis test followed by Dunn\'s Multiple Comparison Test were employed. The results are presented as mean ± SE. Values of p \< 0.05 were considered significant. Statistical analysis was carried out using GraphPad Prism 8 (GraphPad Software, Inc., La Jolla, CA).
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